Developments in synthesis of the anti-inflammatory drug, celecoxib: A review

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 2, 2013, Pages 124-134

  Kumar, Vinod ^a   Kaur, Kamalneet ^a   Gupta, Girish K ^a   Gupta, Akhilesh K ^a   Kumar, Sunil ^b  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^b Govt PG College for Women   (India)

Author keywords

4,4,4 trifluoro 1 4 (methylphenyl) butane 1,3 dione; 4 methylacetophenone; 4 sulphonamidophenyl hydrazine hydrochloride; Anti inflammatory; Anticancer activity; Celecoxib; COX 2 inhibitor

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PRODRUG;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BURN; CRYSTALLIZATION; DERMATITIS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG FORMULATION; DRUG ISOLATION; DRUG MEGADOSE; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; FAMILIAL COLON POLYPOSIS; HUMAN; LEWIS CARCINOMA; LUNG METASTASIS; NONHUMAN; OSTEOARTHRITIS; PAIN; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; HUMANS; INFLAMMATION; PATENTS AS TOPIC; PYRAZOLES; SULFONAMIDES;

EID: 84878663267     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872213X11307020004     Document Type: Review

References (35)

1. Gunduz, H., Bahar, M., Goktepe, M. New crystals of Celecoxib. US20020016351 (2002).
2. Smith WL, Garavito RM, Dewitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases - 1 and -2. J Biol Chem 1996; 271(52): 33157-60.
3. Howel LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cy-clooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8 (2): 97 - 114.
4. Manon B, Sharma PD. Design, synthesis and evaluation of di- clofenac - antioxidants mutual prodrugs as safer NSAIDs. Indian J Chem B 2009; 48 (9): 1279-87.
5. Muppidi, V.M. Process of preparation of Celecoxib crystalline form. EP2363395 (2011).
6. Charugundla, K., Venkateswara, R., Kumar, N., Kumar, P., Prad-han, N., Pradhan, S. Improved process for preparing Celecoxib polymorph. WO2011055233 (2011).
7. Structure of Celecoxib bound at the COX-2 active. Available at:http://www.rsc.org:doi10.2210/pdb3LN1/pdb (Accessed on: November 24, 2012).
8. Uddin, MdJ, Rao PNP, Knaus ED. Design and synthesis of novel celecoxib analogues as Cyclooygenase-2 (COX-2) inhibitors: Replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg Med Chem 2003; 11(23): 5273-80.
9. Mudit D, Keshavarao, KP, Selvam P, Achin J. Enhancing solubility and dissolution of Celecoxib by spray drying technique. IRJP 2012; 3(2): 206-10.
10. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: Preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008; 17(2): 197-208.
11. Chen, C.-S, Chiu, H.-C., Wang, D., Kulp, S.K. The anti-Staphylococcus Celecoxib derivatives. WO2012061260 (2012).
12. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxy-genase-2-independent mechanism. Clin Cancer Res 2005; 11(15): 1999-2007.
13. Park W, Oh YK, Han JH, Pyo H. Antitumor enhancement of Cele-coxib, a selective cyclooxygenase-2-inhibitor, in a lewis lung carcinoma expressing cyclooxygenase-2. J Exp Clin Can Res 2008; 27(66): 1-9.
14. Singh SP, Kumar V, Aggarwal R, Elguero J. The reaction of aryl and heteroarylhydrazines with aryltrifluoromethyl p-diketones. J Het Chem 2006; 43:1003-14.
15. Dadiboyena S, Hamme AT. Synthesis of celecoxib and structural analogs- a review. Curr Org Chem 2012; 16(11): 1390-407.
16. Talley, J.J., Penning, T.D., Collins, P.W., Malecha, J.W., Berten-shaw, S.R., Graneto, MJ. Substituted pyrazolylbenzenesulphona-mides. US5510496 (1996).
17. Zhi, B., Murad, N. Process for preparing 3-haloalkyl-1i7-pyrazoles. US5910597 (1999).
18. Shea, P.O., Tillyer, R.D., Wang, X., Clas, S.D., Dalton, C. Synthesis of 4-[5-substituted or unsubstituted phenyl)-3-substituted-1H-pyrazol-1-yl]benzenesulphonamides. US6150534 (2000).
19. Talley, J.J., Penning, T.D., Collins, P.W., Rogier, D.J., Malecha, J.W., Miyashiro, J.M. Substituted pyrazolylbenzene sulphonamides for the treatment of inflammation. US6156781 (2000).
20. Gunduz, H., Bahar, M., Goktepe, M. Crystals of celecoxib. US6391906B2 (2002).
21. Reddy, M.V.R., Bell, S.C. Processes for the preparation of 1,5-diarylpyrazoles. US6579988B2 (2003).
22. Letendre, L.J., McGhee, W.D., Snoddy, C, Klemm, G., Gaud, H.T. Synthesis of diaryl pyrazoles. US7759497 (2010).
23. Ambati, V.R.R., Garaga, S., Malela, S.P.S., Meenakshisunderam, S. An improved process for the prepartion of Celecoxib. WO2010095024 (2010).
24. Anumula, R.R., Gilla, G., Alla, S., Akki, T.R., Bojja, Y. Process for prepartion of celecoxib. US7919633 (2011).
25. Gaulier SM, McKay R, Swain NA. A novel three-step synthesis of Celecoxib via palladium-catalyzed direct arylation. Tetrahedron Lett 2011; 52 (45): 6000-2.
26. Talley, J.J., Bertenshaw, S. R., Miyashiro, J. M. 4-[5-(4- methylphenyl)-3-(trifluoromethyl) 7i7-pyrazol-1-yl]benzene sul-phonamide for the treatment of inflammation or inflammation associated disorder. USRE44048E (2013).
27. Graneto, M.W., Ewing, G.D. Celecoxib prodrug. US20040092566 (2004).
28. Chowdhury MA, Abdellatif KRA, Dong Y, Yu G, Huang Z, Rahman M, et al. Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: Synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett 2010; 20(4): 1324-9.
29. Lee Y, Kim J, Kang S, Yoon J-H, Kim D-D. N-Succinylaspart-1-yl Celecoxib is a potential colon specific prodrug of Celecoxib with improved therapeutic properties. J Pharm Sci 2012; 101(5):1831-42.
30. Piazza, G.A., Abadi, A.H. Derivatives of Celecoxib, use therof and preparation thereof. WO2012125884 (2012).
31. Chowdhury MA, Abdellatif KRA, Dong Y, Das D, Suresh MR, Knaus EE. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharma-cophore: Biological evaluation as dual inhibitors of cyclooxy-genases and 5-lipoxygenase with anti-inflammatory activity. J Med Chem 2009; 52(6), 1525-9.
32. Chowdhury MA, Abdellatif KRA, Dong Y, Das D, Suresh MR, Knaus EE. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H) one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2008; 18(23), 6138-41.
33. Czarnik, A.W. Deuterium-enriched Celecoxib. US20090062364 (2009).
34. Gao M, Wang M, Miller KD, Hutchins GD, Zheng Q-H. Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation. Appl Radiat Isot 2009; 67(11): 2019-24.
35. Kusunoki N, Ito T, Sakurai N, Handa H, Kawai S. A Celecoxib derivative potentially inhibits proliferation of colon adenocarci-noma cells by induction of Apoptosis. Anticancer Res 2006; 26(5A): 3229-36.